Interesting ...
AZ to showcase AZD0466 on 9 June 2023 at the European Hematology Association (EHA) 2023 Hybrid Congress
https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023.html
- Preliminary ongoing Phase I/II safety and tolerability results of AZD0466, a Bcl-2/Bcl-xl inhibitor, will show it is tolerated as a monotherapy for patients with relapsed or refractory acute leukaemia.
AZD0466
Marconi, G
Safety and tolerability of AZD0466 as monotherapy for patients with advanced hematological malignancies - Preliminary results from an ongoing Phase I/II trial
Abstract # P537
Poster Presentation
9 June 2023
- Forums
- ASX - By Stock
- Astrazeneca-showcases-scientific-advances
Interesting ... AZ to showcase AZD0466 on 9 June 2023 at the...
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.44M |
Open | High | Low | Value | Volume |
11.5¢ | 12.5¢ | 10.5¢ | $132.0K | 1.162M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 535926 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 535926 | 0.115 |
5 | 840444 | 0.110 |
10 | 464030 | 0.105 |
10 | 301472 | 0.100 |
1 | 10305 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 100000 | 1 |
0.130 | 263052 | 6 |
0.135 | 53056 | 4 |
0.140 | 98397 | 7 |
0.145 | 200605 | 6 |
Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
Last
12.0¢ |
  |
Change
0.000 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
11.0¢ | 12.5¢ | 10.5¢ | 991112 | ||
Last updated 15.53pm 03/05/2024 ? |
Featured News
SPL (ASX) Chart |